Association of XPC Polymorphisms with Cutaneous Malignant Melanoma Risk: Evidence from a Meta-Analysis.

Q3 Medicine

Acta medica (Hradec Kralove) Pub Date : 2020-01-01 DOI:10.14712/18059694.2020.27

Fatemeh Asadian, Seyed Mohammadreza Niktabar, Yaser Ghelmani, Shadi Kargar, Elahe Akbarian, Seyed Alireza Emarati, Jalal Sadeghizadeh-Yazdi, Hossein Neamatzadeh

{"title":"Association of XPC Polymorphisms with Cutaneous Malignant Melanoma Risk: Evidence from a Meta-Analysis.","authors":"Fatemeh Asadian, Seyed Mohammadreza Niktabar, Yaser Ghelmani, Shadi Kargar, Elahe Akbarian, Seyed Alireza Emarati, Jalal Sadeghizadeh-Yazdi, Hossein Neamatzadeh","doi":"10.14712/18059694.2020.27","DOIUrl":null,"url":null,"abstract":"Background: A number of studies have reported that the xeroderma pigmentosum complementation group C (XPC) polymorphisms are associated with cutaneous malignant melanoma (CMM) susceptibility. But the results of those studies were inconsistent. Here, we performed a study to obtain a more conclusive result on the association of XPC polymorphisms with risk of CMM.Methods: The XPC Lys939Gln and Ala499Val polymorphisms were genotyped in 150 CMM cases and 150 controls by PCR-RFLP assay. Subsequently, all published relevant studies were identified through a comprehensive literature search in PubMed, Web of Science, and CNKI databases. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to estimate the strength of correlation.Results: There was no significant association between XPC Lys939Gln and Ala499Val polymorphisms and CMM risk in our population. A total of 15 case-control studies including ten studies with 5,990 cases and 7,697 controls on XPC Lys939Gln and five studies with 3,139 cases and 3,721 controls on XPC Ala499Val polymorphism were selected. Pooled data revealed that XPC Lys939Gln (C vs. A: OR = 1.108, 95% CI 1.008- 1.217; P = 0.033) and Ala499Val (C vs. A: OR = 0.918, 95% CI 0.850-0.992; p = 0.031; CC+CA vs. AA: OR = 0.904, 95% CI 0.819-0.997; p = 0.043) polymorphisms were significantly associated with an increased risk of CMM. Moreover, stratified analyses by ethnicity revealed that the XPC Ala499Val and Lys939Gln polymorphisms were significantly associated with risk of CMM in Caucasians and mixed populations, respectively.Conclusions: This meta-analysis result suggested that XPC Lys939Gln and Ala499Val polymorphisms were significantly associated with risk of CMM.","PeriodicalId":35758,"journal":{"name":"Acta medica (Hradec Kralove)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta medica (Hradec Kralove)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14712/18059694.2020.27","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 1

Abstract

Background: A number of studies have reported that the xeroderma pigmentosum complementation group C (XPC) polymorphisms are associated with cutaneous malignant melanoma (CMM) susceptibility. But the results of those studies were inconsistent. Here, we performed a study to obtain a more conclusive result on the association of XPC polymorphisms with risk of CMM.

Methods: The XPC Lys939Gln and Ala499Val polymorphisms were genotyped in 150 CMM cases and 150 controls by PCR-RFLP assay. Subsequently, all published relevant studies were identified through a comprehensive literature search in PubMed, Web of Science, and CNKI databases. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to estimate the strength of correlation.

Results: There was no significant association between XPC Lys939Gln and Ala499Val polymorphisms and CMM risk in our population. A total of 15 case-control studies including ten studies with 5,990 cases and 7,697 controls on XPC Lys939Gln and five studies with 3,139 cases and 3,721 controls on XPC Ala499Val polymorphism were selected. Pooled data revealed that XPC Lys939Gln (C vs. A: OR = 1.108, 95% CI 1.008- 1.217; P = 0.033) and Ala499Val (C vs. A: OR = 0.918, 95% CI 0.850-0.992; p = 0.031; CC+CA vs. AA: OR = 0.904, 95% CI 0.819-0.997; p = 0.043) polymorphisms were significantly associated with an increased risk of CMM. Moreover, stratified analyses by ethnicity revealed that the XPC Ala499Val and Lys939Gln polymorphisms were significantly associated with risk of CMM in Caucasians and mixed populations, respectively.

Conclusions: This meta-analysis result suggested that XPC Lys939Gln and Ala499Val polymorphisms were significantly associated with risk of CMM.

查看原文本刊更多论文

XPC 多态性与皮肤恶性黑色素瘤风险的关系：一项 Meta 分析的证据。

背景：许多研究报告称，色素性皮肤病补体C组（XPC）多态性与皮肤恶性黑色素瘤（CMM）易感性有关。但这些研究的结果并不一致。在此，我们对 XPC 多态性与 CMM 风险的相关性进行了研究，以获得更确切的结果：方法：通过 PCR-RFLP 法对 150 例 CMM 病例和 150 例对照进行 XPC Lys939Gln 和 Ala499Val 多态性基因分型。随后，通过在PubMed、Web of Science和CNKI数据库中进行全面文献检索，确定了所有已发表的相关研究。计算了相关系数（OR）和95%置信区间（CI），以估计相关性的强度：结果：在我国人群中，XPC Lys939Gln和Ala499Val多态性与CMM风险之间没有明显关联。共选择了 15 项病例对照研究，包括 10 项关于 XPC Lys939Gln 的研究（5990 例病例和 7697 例对照）和 5 项关于 XPC Ala499Val 多态性的研究（3139 例病例和 3721 例对照）。汇总数据显示，XPC Lys939Gln（C vs. A：OR = 1.108，95% CI 1.008- 1.217；P = 0.033）和Ala499Val（C vs. A：OR = 0.918，95% CI 0.850-0.992；P = 0.031；CC+CA vs. AA：OR = 0.904，95% CI 0.819-0.997；P = 0.043）多态性与CMM风险增加显著相关。此外，按种族进行的分层分析显示，XPC Ala499Val 和 Lys939Gln 多态性分别与白种人和混血人群的 CMM 风险显著相关：这项荟萃分析结果表明，XPC Lys939Gln和Ala499Val多态性与CMM风险显著相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta medica (Hradec Kralove) Medicine-Medicine (all)

CiteScore

1.10

自引率

0.00%

发文量

审稿时长

20 weeks

期刊介绍： Acta Medica (Hradec Králové) is a multidisciplinary medical journal published by the Faculty of Medicine in Hradec Králové - Karolinum Press, the publishing house of Charles University. The journal is peer-reviewed and published quarterly in both paper and electronic form. The language of Acta Medica is English. Offerings include review articles, original articles, brief communications, case reports, announcements and notices. The journal was founded in 1958 under the title "A Collection of Scientific Works of the Charles University Faculty of Medicine in Hradec Kralove."